Susan R. Winkler, PharmD, BCPS, FCCP
- Professor and Chair, Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois
Important interactions and unwanted effects Frequent rectal administration can result in proctitis elbow pain treatment bursitis buy sulfasalazine 500 mg line. Do not leave undiluted in a plastic syringe for any longer than necessary as it will dissolve the syringe: dilute and administer promptly! Missed dose regimen If one or more doses have been missed and breakthrough seizures have occurred pain treatment center memphis purchase sulfasalazine no prescription, consider giving a single additional partial loading dose (e treatment for nerve pain from shingles buy sulfasalazine on line amex. Preparations Tablets (15 chiropractic treatment for shingles pain order sulfasalazine 500mg with mastercard, 30 valley pain treatment center az cheap sulfasalazine online, and 60 mg; may be crushed) pain and spine treatment center nj order 500mg sulfasalazine with mastercard, elixir (unpleasant taste; some preparations contain alcohol), intravenous injection (60 mg/mL, 200 mg/mL). Dose requirements are toward the top end of this range (sometimes higher) in neonates and infants. Missed dose regimen If one or more doses have been missed and breakthrough seizures have occurred, consider giving an additional partial loading dose (e. Important interactions and unwanted effects Nausea, headache, tremor, ataxia (dose-dependent). Osteomalacia (consider calcium/vitamin D supplementation if prolonged treatment is anticipated). Gum hyperplasia may be limited by scrupulous attention to teethcleaning (it is accelerated by the presence of plaque). Dental surgeons can offer cosmetic gum resection in established cases where continuing phenytoin use is required. Phenytoin is highly protein bound and levels may need to be adjusted for serum albumin. Intravenous phenytoin infusion is strongly alkaline and must be infused slowly into a large vein to avoid phlebitis and/or tissue injury due to extravasation. Due to its need for conversion to phenytoin it is not clear that the faster infusions of fosphenytoin possible necessarily lead to earlier establishment of therapeutic brain phenytoin levels. Intravenous infusions of both fosphenytoin and phenytoin have been associated with severe cardiac arrhythmias. It is common to see inexperienced prescribers struggling with over- and undershooting levels. The main reason for this is failure to appreciate how long it takes to establish a new steady-state drug level after a dose change, 2 which is often several days and for phenytoin can be up to 2 weeks. The loading dose does not influence the steady-state level ultimately achieved, which is determined solely by the maintenance dose. Thus, if a blood level is still low and seizures are occurring a few days after starting phenytoin, give a further partial load (e. Adjustments of maintenance doses in light of steady-state blood levels should be in small increments (<10% previous dose). Important interactions and unwanted effects Some sedation, serious arrhythmias; glycosuria and rarely hyponatraemia. Important interactions and unwanted effects Weight gain, nervousness, hyperkinesia, and less commonly drowsiness, and depression. Important interactions and unwanted effects Dry mouth, constipation, increased appetite and weight gain, drowsiness. Prednisolone (prednisone) Neurological indications Treatment of infantile spasms and epileptic encephalopathies. If dose increased to 20 mg tds for 7 days, reduce to 40 mg/24 h for 5 days then 20 mg/24 h for 5 days then 10 mg/24 h for 5 days then stop. Comments Prolonged steroid treatment over months requires monitoring of bone mineral density and calcium/vitamin D supplementation. Gastric protection with a protonpump inhibitor or H2-antagonist may be required at high doses or prolonged courses. Pregabalin Neurological indications Neuropathic pain and paraesthesiae; also adjunctive treatment of focal seizures). Dosing Starting doses and escalation regimen Over 12 yrs: 75 mg/24 h divided in 3 doses; 75 mg/24 h increments at weekly intervals. Procyclidine Neurological indications Emergency treatment of acute dystonia and oculogyric crises. Preparations Tablets (10, 40, 80, and 160 mg), oral solution (5 mg/5 mL, 10 mg/5 mL, 50 mg/5 mL). Important interactions and unwanted effects Postural hypotension at excessive doses. Important interactions and unwanted effects Nausea, vomiting, increased salivation, abdominal cramps. Pyridoxal phosphate Neurological indication Refractory epilepsy in infants (may be superior to pyridoxine). Pyridoxine (vitamin B6) Neurological indications Treatment of refractory epilepsy in infants (see b p. Preparation Tablets (10, 20, and 50 mg; can be halved, quartered, or crushed and dissolved in water), injection (50 mg/2 mL), liquid. Try not to make any other changes in anti-epileptics during this period to aid interpretation (see b p. The dose for optimal neurodevelopmental outcome may be greater than the dose that controls seizures. Comments Use of antipsychotics to manage acutely disturbed behaviour should only be considered in extreme situations (e. Rufinamide Neurological indications Epilepsy, particularly Lennox-Gastaut syndrome. Preparations 100, 200, and 400 mg tablets, which may be crushed and mixed with water. Important interactions and unwanted effects May raise phenytoin levels; metabolism inhibited by valproate. Comments A serious hypersensitivity syndrome has been reported in children after initiating therapy; consider withdrawal if rash or signs or symptoms of hypersensitivity syndrome develop. Stiripentol Neurological indications Anti-epileptic drug particularly for severe myoclonic epilepsy of infancy (Dravet Syndrome). Comments Most commonly used in conjunction with valproate and/or clobazam in treatment of severe myoclonic epilepsy of infancy (see b p. Important interactions and unwanted effects Antimuscarinic effects; may cause agitation in low dose, hepatitis. Contraindications Vasospasm, previous cerebrovascular accident or transient ischaemic attack, peripheral vascular disease, hypertension. Important interactions and unwanted effects Taste disturbance, mild irritation or burning sensation in the nose or throat, heat, heaviness, pressure or tightness, flushing in any part of the body, dizziness, weakness, fatigue, drowsiness and transient increases in blood pressure. Other triptans are not direct equivalents: rizatriptan has a short half-life, and frovatriptan has a much longer half-life than sumatriptan. Important interactions and unwanted effects Interacts with metoclopramide: increased risk of dystonia. Important interactions and unwanted effects Nausea, diarrhoea, sleepiness, tremor, rarely non-convulsive status epilepticus. Important interactions and unwanted effects Interacts with ciprofloxacin and phenytoin. Important interactions and unwanted effects Nausea, anorexia with weight loss, paraesthesiae. Contraindications Intestinal obstruction, urinary retention, closed angle glaucoma, myasthenia gravis. Important interactions and unwanted effects Urinary retention, constipation, tachycardia, anhidrosis (and hyperpyrexia), dry mouth, blurred vision, confusion, agitation, hallucination. Gradual dose escalation can result in children tolerating comparatively high doses. Preparations Crushable tablet (100 mg) enteric-coated tablets (200 and 500 mg) controlled-release tablet (200, 300, and 500 mg), oral liquid (200 mg/5 mL), intravenous injection (100 mg/mL) modified-release granules (50, 100, 250, 500, and 750 mg, and 1 g). Impaired hepatic function leading rarely to fatal hepatic failure (some cases likely to be due to unidentified beta-oxidation or mitochondrial depletion (Alper) syndromes: avoid use if mitochondrial disease suspected). Teratogen causing distinct foetal valproate syndrome and/or neural tube defects, and possible adverse developmental outcomes in babies exposed in utero (see b p. Comments Routine monitoring of liver function in an asymptomatic child is not indicated. Carers should be taught to seek medical attention in case of unexplained nausea, vomiting, darkened urine or jaundice. Vigabatrin Neurological indications Treatment of infantile spasms particularly in tuberous sclerosis. Dosing Starting doses and escalation regimen Infantile spasms: 50 mg/kg/24 h increasing if required every 48 h to 100 mg/kg/24 h and then 150 mg/kg/24 h divided in 2 doses. Powder can be dispersed in 10 mL of water and the appropriate volume used to give small doses. Contraindications Pre-existing or potential for visual impairment (particularly visual field impairments). Contraindications Severe gastritis or ulcer, severe hypertension, bacterial endocarditis. Pain and paresthesias in the distribution of the median nerve are the classic symptoms. Conservative treatment options include splinting the wrist in a neutral position and ultrasound therapy. Orally administered corticosteroids can be effective for short-term management (two to four weeks), but local corticosteroid injections may improve symptoms for a longer period. A recent systematic review demonstrated that nonsteroidal anti-inflammatory drugs, pyridoxine, and diuretics are no more effective than placebo in relieving the symptoms of carpal tunnel syndrome. If symptoms are refractory to conservative measures or if nerve conduction studies show severe entrapment, open or endoscopic carpal tunnel release may be necessary. Carpal tunnel syndrome should be treated conservatively in pregnant women because spontaneous postpartum resolution is common. Clinical Features the classic symptoms of carpal tunnel syndrome are pain, numbness, and tingling in the distribution of the median Although 30 percent of frequent computer users complain of hand paresthesias, only 10 percent meet clinical criteria for carpal tunnel syndrome, and nerve conduction studies are abnormal in only 3. This article reviews the clinical features, diagnosis, and treatment of this relatively common condition. C nerve (Figure 1), although numbness in all fingers may be a more common presentation. To relieve the symptoms, patients often "flick" their wrist as if shaking down a thermometer (flick sign). In patients with carpal tunnel syndrome, pain and paresthesias may radiate to the forearm, elbow, and shoulder. Decreased grip strength may result in loss of dexterity, and thenar muscle atrophy may develop if the syndrome is severe.
Comorbidities: not reported Cointerventions: not reported 240 mL whole milk valley pain treatment center phoenix purchase sulfasalazine 500mg without a prescription, 90% hydrolyzed (lactose content 1 back pain treatment during pregnancy generic sulfasalazine 500 mg with visa. Dakota Diary Foods Maldigesters were reported lactose content 15 Conclusion(s): Research Center classified on the basis Comorbidities: not 16 g) neck pain treatment youtube buy sulfasalazine line. Duration of hydrogen concentration Cointerventions: acidophilus B (b acidophilus N1 was symptom recording: of >20 ppm after not reported gal) activity 0 pain treatment alternative generic 500 mg sulfasalazine visa. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author pain management utica new york sulfasalazine 500mg with mastercard, Year pain treatment center seattle wa buy sulfasalazine with a visa, Study Design, Study Sponsorship, Country, Length of Followup 8 hours Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria ingestion of 400 ml of milk containing approxi mately 18 g of lactose. Methods to measure outcomes: Subjects rated symptoms on a 0 5 (none to severe) scale for each hour from hour 1 to hour 8 following each of the diets. Data source: 15 American volunteers Inclusion criteria: lactose maldigesters on basis of rise of >20ppm after ingestion of 400 ml of milk (16 gm lactose) on hydrogen breath test using Levitt/Donaldson method. Methods to measure outcomes: ranked scale of symptoms for abdominal pain, flatulence, borborygmi, diarrhea and meteoism: 0=none, 1=slight, 2=mild, 3=moderate, 4=moderately severe, 5= severe summed for hours 1-8. TreatmentControl, Adherence Evaluations Outcome assessment/ Results and Conclusions the four strains in improving lactose digestion and tolerance. Conclusion(s): Consumption of milk containing B6 grown with lactose resulted in significantly less flatulence vs. Inclusion criteria: lactose intolerance on the basis of an increase in breath hydrogen concentration >20 ppm after ingestion of 440 mL milk containing 18 g lactose. Methods to measure outcomes; No methods Subject Characteristics Treatment-Active, Adherence Evaluations TreatmentControl, Adherence Evaluations Outcome assessment/ Results and Conclusions a higher galactosidase level and increase rate of lactose uptake. France Duration of symptom recording: unclear Age range: 20-45 Gender: women 11 (73%) Race: 100% Caucasian Comorbidities: none Cointerventions: not reported 3 fermented dairy products each with 18gm lactose in 250 ml water: 1) Ofilus (Yoplait, France; has L. Comorbidities: not reported Cointerventions: not reported 125 g yogurt (n=8) three times daily (breakfast, bunch, and dinner) (lactose content 18 g/d) Meals were given over 8 consecutive days. These Allocation concealment: unclear Blinding: double Intent-to-treat analyses: 100% followup Study withdrawals adequately described: no withdrawals reported D-383 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria reported. Subject Characteristics Treatment-Active, Adherence Evaluations TreatmentControl, Adherence Evaluations Outcome assessment/ Results and Conclusions data indicate that besides lactose digestion, other factors are involved in inducing or preventing gastrointestinal distress during the consumption of dairy products by lactasedeficient subjects. Conclusion(s): Subjects were free of symptoms after consuming flavored and unflavored yogurts. Flavored (lactose content 20 products (n=9) g) 1) 465 g strawberry flavored yogurt (lactose content 20 g) 2) 410 g ice milk (lactose content 20 g) 3) 400 g ice cream (lactose content 20g) B. Allocation concealment: unclear Blinding: singleblind (subjects were not informed of the identity of each product but no attempt to mask flavors was undertaken) Intent-to-treat analyses: 100% followup Study withdrawals adequately described: no withdrawals reported D-384 Appendix Table D8. Inclusion criteria: lactose intolerance on the basis of an increase in breath hydrogen concentration >20 ppm after ingestion of milk containing 20 g lactose. Methods to measure outcomes; intolerance symptoms were recorded by the subjects, scale not reported. Symptoms reported were diarrhea, flatulence, abdominal pain Subject Characteristics Treatment-Active, Adherence Evaluations 1) 500 gm yogurt 2) 420 gm sweet acidophilus milk 3) 465 gm cultured milk (buttermilk) 4) 500 gm pasteurized yogurt TreatmentControl, Adherence Evaluations 410 gm milk Outcome assessment/ Results and Conclusions No symptoms reported when yogurt or pasteurized yogurt was fed. Symptoms score referred to the 5 days preceding each evaluation and scored as: 0=absent; 1=mild (awareness of a Mean age: 44 Gender: women 80%. Conclusion(s): the total symptom score significantly improved after rifaximin and lactose-free diet. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria symptom but easily tolerated); 2=moderate; 3=severe; and 4=very severe. Subjects 10 days were classified as lactose maldigesters based on a rise in breath hydrogen of >20 ppm (0. Methods to measure outcomes: Subjects rated symptoms hourly during the breath hydrogen tests using a ranked scale: 0=none, 1=slight, 2=mild, 3=moderate, 4= moderately severe, 5= severe. Data are reported as the sum of Subject Characteristics Treatment-Active, Adherence Evaluations TreatmentControl, Adherence Evaluations Outcome assessment/ Results and Conclusions Quality of the Study Mean age: 30 Gender: women 25%. Race: Asian 70%, black, LatinAmerican, and white 10% each Comorbidities: not reported Cointerventions: not reported Dextrose for days 1-10 and crossed over to the other feeding period for days 12-21. Breath hydrogen excretion and intolerance symptoms were monitored hourly for 8 hours after the challenge dose was consumed Lactose for days 1 10 and crossed over to the other feeding period for days 12-21. Breath hydrogen excretion and intolerance symptoms were monitored hourly for 8 hours after the challenge dose was consumed. The maximum possible score for any individual symptom would be 40 (a "5" rating each hour for 8 hours). Conclusion(s): Authors concluded that there is colonic adaptation to regular lactose ingestion and this adaptation reduces lactose intolerance symptoms. Allocation concealment: unclear Blinding: noted as blinded, unclear if double-blinded Intent-to-treat analyses: no Study withdrawals adequately described: no D-386 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria hours 1-8. During the feeding periods, subjects recorded symptoms once per day each evening during the feeding periods using the same scale mentioned above. Gender: women of lactose dissolved Sponsorship: Minnesota Inclusion criteria: 46%. Methods to measure outcomes: Subjects rated symptoms of flatulence, abdominal pain, and diarrhea hours 1 through 8 following challenge dose. A ranked scale was used; 0=none, 1=slight, 2=mild, 3=moderate, 4= moderately severe, 5= severe. Conclusion(s): Lactose maldigesters may be able to tolerate foods with 6 g lactose per serving such as hard cheeses and small servings (120 mL) of milk. Allocation concealment: unclear Blinding: doubleblinded Intent-to-treat analyses: no Study withdrawals adequately described: no Number of subjects with symptoms. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup National Institutes of Health and United States Public Health Service. Methods to measure outcomes: A subject was considered to have a positive symptomatic response if he/she had 1 loose stools or had a grade 2+ or higher in at least one of the following symptoms: abdominal cramps/pain, bloating or gas, borborygmi, flatulence. Symptoms were rated according: 0 = no trouble; 1+ = slight; 2+ = mild; 3+ = moderate, subject would normally avoid a breakfast causing these symptoms; 4+ = severe, subject would be unable to carry on usual activities. Those with no symptoms got 100, 150 and Placebo 250 ml (saccharin, lemon juice water) Sum of score of bloating, gas, cramps and diarrhea on scale: 0=none, 1=mild, 2= moderate, 3=severe. Conclusion(s): Most adults with lactose Allocation concealment: unclear Blinding: single no masking Intent-to-treat analyses: one person lost to D-388 Appendix Table D8. Age symptom recording: positive in 33 (27%) and <50 years 73%; 1 week negative in 89 (73%). Gender: women Subjects in the positive 76% group were then placed Race/ethnicity on a low lactose diet for White 85% (n=28), 3 weeks. The daily Asian 9% (n=3), intake of lactose from Middle-Eastern 6% this diet was <1 g. Subjects remained on low lactose diet during double-blind, placebo-controlled test period. Conclusion(s): During double-blind phase, 2/7 subjects (29%) developed increasing symptoms with increasing doses of lactose. Allocation concealment: unclear Blinding: doubleblinded Intent-to-treat analyses: 100% followup although 2 subjects meeting eligibility did not participate for unknown reasons Study withdrawals adequately described: no withdrawals reported D-389 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria flatulence, headache, abdominal distension, and general well-being. Subjects had to fulfill at least two criteria: visible abdominal distension; pain relief with defecation; more frequent stools at pain onset; looser stools at pain onset; passage of rectal mucus; and feeling of incomplete evacuation. Allocation concealment: unclear Blinding: doubleblinded Intent-to-treat analyses: no dropouts reported Study withdrawals adequately described: none D-390 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria during a challenge dose of lactose (50 g) after a 12 hours fast. Methods to measure outcomes: subjects scored symptoms (pain, flatulence, distension, diarrhea, mucus, incomplete evacuation) 0=no complaints, 1=mild; 2=moderate; and 3 as severe. Kligerman, President of Sugar Lo/Lact Aid company (lactase and placebo vials) Mexico Duration of symptom recording: months: 3 months Mean age (range): 49 years (24 to 72) Gender: women 75% Race/ethnicity: not reported Comorbidities: not reported Cointerventions: not reported Treatment A group Lactase x 4 weeks, then placebo x 4 weeks, then lactase x 4 weeks. Prior to 3 month study phase there was a 1 month non intervention, control period. Lactase (derived from Kluyveromyces lactis) was used in vitro (added in entirety to liter of milk the day before consumption) and in vivo (added at mealtime when consuming lactosecontaining foods away from home) Treatment B group Placebo x 4 weeks, then lactase x 4 weeks, then lactase x 4 weeks. Allocation concealment: unclear Blinding: doubleblinded Intent-to-treat analyses: 100% followup Study withdrawals adequately described: no withdrawals reported D-391 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria to allow adherence to frequent interviews; and 4) showed proper compliance and reliability during first (control) month. Symptoms included constipation, diarrhea, abdominal pain, abdominal distension, and flatulence. Inclusion criteria: lactase deficiency was diagnosed by an increase in the breath hydrogen 0. Cumulative symptom indices for the 18 lactase deficiency subjects Conclusion(s): There was no difference in the tolerance of the acidophilus and unaltered milks in the lactase deficient group. Allocation concealment: unclear Blinding: doubleblinded Intent-to-treat analyses: 100% followup Study withdrawals adequately described: no withdrawals reported D-392 Appendix Table D8. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) Author, Year, Study Design, Study Sponsorship, Country, Length of Followup Subject Selection, Data Source, Methods to Measure Outcomes, Inclusion/Exclusion Criteria outcomes: Symptom (diarrhea, abdominal pain/cramps*, gas/flatus*, rumbling*, constipation) diary at end of each day. Scored as following for *: 0=no trouble; 1=slight trouble; 2=mild; 3=moderate; 4=severe. Subject Characteristics Treatment-Active, Adherence Evaluations TreatmentControl, Adherence Evaluations Outcome assessment/ Results and Conclusions Quality of the Study D-393 References for Appendix D (Note that this set of references is different from those in the text of the report and the numbers are different. Molecularly defined lactose malabsorption, peak bone mass and bone turnover rate in young finnish men. Genetic variant of lactase-persistent C/T-13910 is associated with bone fractures in very old age. Molecularly-defined lactose malabsorption, milk consumption and anthropometric differences in adult males. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) 19. Impact of molecularly defined hypolactasia, self-perceived milk intolerance and milk consumption on bone mineral density in a population sample in Northern Europe. Perceived milk intolerance is related to bone mineral content in 10- to 13-year-old female adolescents. Adult-type hypolactasia and calcium availability: decreased calcium intake or impaired calcium absorption? Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. Children who avoid drinking cow milk have low dietary calcium intakes and poor bone health. Long-term vegetarian diet and bone mineral density in postmenopausal Taiwanese women. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) 37. Bone mineral density in Chinese elderly female vegetarians, vegans, lacto-vegetarians and omnivores. Positive effects of vegetable and fruit consumption and calcium intake on bone mineral accrual in boys during growth from childhood to adolescence: the University of Saskatchewan Pediatric Bone Mineral Accrual Study. Nonalcoholic carbonated beverage consumption and bone fractures among women former college athletes. Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebocontrolled trial in prepubertal boys. Effect of exogenous beta-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) 56. Lactose maldigestion is not an impediment to the intake of 1500 mg calcium daily as dairy products. Treatment of lactose intolerance with exogenous beta-D-galactosidase in pellet form. Tolerance to the daily ingestion of two cups of milk by individuals claiming lactose intolerance. Comparative effects of exogenous lactase (beta galactosidase) preparations on in vivo lactose digestion. Calcium absorption and acceptance of lowlactose milk among children with primary lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of beta-galactosidase to milk at mealtime. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) 75. Comparative tolerance of elderly from differing ethnic backgrounds to lactose-containing and lactose-free dairy drinks: a double-blind study. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Lactose malabsorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. Evidence table for blinded lactose intolerance treatment studies: Question 4 (continued) 92. Our specialists are dedicated to supporting your team with all aspects of pre-authorization processes, case management, and reimbursement matters. We have taken this opportunity to provide you with a Pre-Authorization packet containing required paperwork for each case as well as sample letters of medical necessity and candidate clearance. Nuvectra Connect Pre-Authorization 5830 Granite Parkway, Suite 1100 Email: preauth@nuvectramed.
Since the avoidance of milk and milk containing products can result in a dietary calcium intake that is below recommended levels of 1 topical pain treatment for shingles purchase cheapest sulfasalazine and sulfasalazine,000 milligrams (mg) per day for men and women and 1 treatment for pain in uti 500mg sulfasalazine for sale,300 mg for adolescents homeopathic pain treatment for dogs buy sulfasalazine 500 mg amex, osteoporosis and associated fractures secondary to inadequate dietary calcium is the perceived major potential health problem associated with real or assumed lactose intolerance oceanview pain treatment medical center generic sulfasalazine 500 mg mastercard. Current dietary recommendations suggest consuming 3 cups/day of fat-free or low-fat milk or equivalent milk products pain medication for senior dogs 500mg sulfasalazine sale. Treatment to reduce lactose exposure pain treatment centers of america colorado springs buy 500 mg sulfasalazine mastercard, while maintaining calcium intake from dairy products, consists of a lactose restricted diet or the use of milk in which the lactose has been prehydrolyzed via treatment with lactase supplements. Lactase supplements taken at the time of milk ingestion also are commercially available. Congenital lactase deficiency, a very rare condition in which lactase synthesis is negligible at birth, results from the inheritance of two defective alleles of the lactase transcribing gene located on chromosome 2. Secondary lactase deficiency occurs in diseases that damage the brush border, such as celiac disease or intestinal infections. Lactase nonpersistence is a condition in which lactase synthesis is normal at birth and throughout infancy. However, after weaning, lactase synthesis declines, and by adulthood brush border lactase concentrations are only about 10 percent of the infantile level. This review will focus solely on the problems associated with lactase nonpersistence. In lactose nonpersistent subjects the activity of this promoter is programmed to decline markedly after weaning, with a resultant decline in lactase synthesis. Several population groups, most prominently individuals of northern European extraction, have mutations of this promoter which permits it to remain active throughout life. In northern Europeans, a single nucleotide thymine for cytosine substitution in the promoter region allows this gene to retain activity throughout adulthood with resultant lactase persistence. Direct assessment of brush border lactase levels requires analysis of biopsies of small bowel mucosa via either measurement of enzymatic activity or histochemical staining for lactase. The complexity and expense of these techniques has limited their application, and information concerning the lactase nonpersistence/persistence state of individuals largely has been inferred from measurements of lactose absorption. The Digestive Diseases Clearinghouse of the National Institute of Diabetes, Digestive and Kidney Diseases states that 30 million to 50 million individuals in this country and about 4 billion people worldwide are lactase nonpersisters. Many of these individuals belong to minority groups such as Asians, African Americans, Hispanics, Native Americans, Alaskan Natives, and Pacific Islanders. However, lactase nonpersistence is also observed in a sizable fraction of Caucasians of southern European and Mediterranean origin. Lactose Malabsorption Multiple tests have been employed to assess the ability of a subject to absorb lactose. This test largely has been supplanted by the hydrogen H2 breath test, which assesses breath H2 concentration following ingestion of a 50 gram dose of lactose. A rise in breath H2 signifies that lactose has reached the colonic bacteria and hence was malabsorbed. Various lactose dosages, times of breath collection, and breath H2 increases have been employed in this test, and the accuracy of hydrogen H2 breath testing for lactose malabsorption has never been precisely determined. Nevertheless, this simple noninvasive test has been widely employed and much of our knowledge concerning the prevalence of lactose malabsorption in various population groups, as well as the ability of individual patients to absorb lactose, has been obtained via hydrogen H2 breath testing. Lactose Intolerance Lactose intolerance indicates that malabsorption of lactose results in symptoms of diarrhea, flatulence, bloating, or abdominal discomfort. Intolerance to supra 21 physiological loads of lactose (such as were employed in the lactose tolerance test) does not necessarily indicate that subjects will be symptomatic with a smaller, more physiological dosage. Thus, the dosage of lactose that causes symptoms is a major consideration in determining the importance of lactose as a clinical problem. Another important question is the extent to which the colon of select individuals might be particularly sensitive to lactose and/or its bacterial metabolites; e. Treatment to reduce lactose exposure consists of a lactose restricted diet or the use of lactase supplements. The former may involve the avoidance of milk and milk-containing foods or the use of milk in which the lactose has been pre-hydrolyzed via treatment with lactase. Women who are pregnant or breastfeeding need between 1,000 and 1,300 mg of calcium daily. Because dairy foods are the major source of dietary calcium intake (in the absence of supplementation), dietary recommendations suggest consuming 3 cups/day of fat-free or low-fat milk or equivalent milk products. Recommended calcium intake by age group Age Group 0-6 months 7-12 months 1-3 years 4-8 years 9-18 years 19-50 years 51-70+ years Amount of Calcium to Consume Daily, Age Group in Milligrams (mg) 210 mg 270 mg 500 mg 800 mg 1,300 mg 1,000 mg 1,200 mg Source: Adapted from Dietary Reference Intakes, 2004, Institute of Medicine, National Academy of Sciences. Calcium content in common foods Nonmilk Products Rhubarb, frozen, cooked, 1 cup Sardines, with bone, 3 oz. Milk and Milk Products Yogurt, with active and live cultures, plain, low-fat, vitamin D-fortified, 1 cup Milk, reduced fat, vitamin D-fortified, 1 cup Swiss cheese, 1 oz. Tolerable Dose of Lactose Symptoms induced by lactose malabsorption (lactose intolerance) result from: (a) fluid osmotically "held" in the gut by nonabsorbed lactose and its bacterial metabolites and (b) gases released by the bacterial fermentation of lactose. It follows that very low doses of lactose should be tolerated without symptoms, while very large doses should routinely induce symptoms. Lactase nonpersistent subjects retain a low, but readily measureable, concentration of lactase in the brush border of their small bowel, and intubation studies have shown that these subjects are capable of absorbing variable amounts (mean: about 40 percent) of a 12 gram dose of lactose. The kinetics of this digestion have not been studied, but it seems likely that the 12 gram dose of lactose saturates the digestive activity of the gut, such that the percentage absorption would decline with increasing lactose loads. It is possible that there are appreciable differences in the residual lactase activity of lactase nonpersistent subjects, with resultant sizable differences in their ability to digest and absorb a given dose of lactose. Differences in small bowel transit time (partially a function of gastric emptying) could affect the ability of this limited lactase activity to act on luminal lactose. If the osmotic load created by nonabsorbed lactose was simply a function of the amount of lactose reaching the colon, the potential for nonabsorbed lactose to increase fecal water and induce diarrhea would be predictable: a gram of lactose is equivalent to 3 mosms and fecal water 23 is isotonic (about 300 mosm/l). Thus, 12 grams of lactose (36 mosm), the quantity in 1 cup of milk, would osmotically hold 36/300 of a liter of fluid in the lumen or about 120 ml. Normally, humans excrete about 100 ml of fecal water each day, and increasing this quantity by 120 ml would yield a loose stool but not severe diarrhea. However, the vast majority of malabsorbed lactose is fermented by the colonic bacteria to short chain organic acids, which are rapidly taken up by the colonic mucosa. When relatively low amounts of lactose reach the colon, fermentation and subsequent absorption of lactose metabolites may be sufficiently rapid to remove all lactose and its metabolites from the fecal stream, thus protecting the subject from lactose-induced diarrhea. However, as the lactose load increases, the production of bacterial metabolites may outstrip the ability of the colonic mucosa to remove these metabolites. In this situation, bacterial metabolism increases the osmotic load over that of lactose with a resultant increase in fecal volume. Thus, differences in fecal bacterial metabolism, colonic mucosal function, and colonic transit time influence the susceptibility of individual subjects to develop diarrhea following malabsorption of lactose. Adaption of the colonic flora via a shift to nongas producing pathways is considered to be the explanation for the decreased H2 excretion that occurs following daily exposure to large doses of lactose. This fermentation pathway could reduce the distention and flatulence noted with lactose malabsorption. In addition, several other bacterial reactions utilize H2, and H2 released from fecal material is only a small fraction of that produced. The luminal gases that escape metabolism and absorption are excreted per the anus and thus have the potential to increase flatus volume and frequency. Since there are individual differences in the gas producing and consuming reactions, it would be expected that the volume of luminal gas resulting from malabsorption of a given quantity of lactose might vary widely from one subject to the next. Subjects with a "hypersensitive" colon may rapidly propel nonabsorbed lactose and its metabolites through the colon with resultant diarrhea and flatulence, while slower transit in the less sensitive colon could allow for more complete absorption of the metabolites, hence no diarrhea or flatulence. Similarly, the hypersensitive colon might perceive discomfort with a degree of distention that was imperceptible to subjects with a less sensitive colon. The above theoretical discussion suggests that there could be wide individual differences in the daily dose of lactose that is tolerable to subjects with lactose nonpersistence. Elucidation of this tolerable dose can only be obtained from a study of the subjective response of subjects to ingestion of known dosages of lactose. Strategies to Manage Individuals with Diagnosed Lactose Intolerance Lactose is a simple disaccharide composed of glucose and galactose linked by a beta 1,4 bond. Intestinal brush border synthesizes lactase, an enzyme that is able to cleave the beta 1,4 bond. The current definition by the Food and Drug Administration and the World Health Organization is "Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host. These microorganisms can be added to food products, such as milk and yogurt, or used as supplements. Examples of commonly used probiotics include lactobacillus, bifidobacterium, and saccharomyces. Enzyme replacement therapy with lactase from nonhuman sources to hydrolyze lactose in another important approach to preventing lactose intolerance. There are multiple commercially available lactase supplements containing variable amounts of beta-galactosidase from a variety of sources. In addition, lactose reduced milk is also available commercially, with lactose content of 5 percent to 90 percent of regular milk. Probiotics and lactase supplements are often regulated as dietary supplements rather than pharmaceuticals or biological agents. Hence, there is no requirement to demonstrate efficacy, purity, potency, or safety prior to marketing probiotics and supplements. The access to the World Wide Web and direct consumer marketing has inundated the public with promotional information, while scientific evidence to support use has been largely overlooked. This is supported by the observation that introduction of lactose to diet causes temporary and transient symptoms in individuals. Other strategies for management of lactose intolerance include gut decontaminating agents and anti-microbials, such as rifaximin. Methods Overview Analytic Framework We followed the analytic framework (modified from the U. Preventive Services Task Force)8 to determine causality between treatments and patient outcomes and adverse events in patient subpopulations, including age, race, and ethnic subgroups. Probabilities of diagnosis, treatment, and outcomes were analyzed based on the published literature. What are the intermediate and clinical outcomes of lactose free or low lactose diets? What amount of daily lactose intake is tolerable in subjects with diagnosed lactose intolerance? What are the intermediate, clinical, and adverse outcomes after treatments for lactose intolerance? In the clinical situation, a graduated definition of a potentially lactose intolerant subject, might be as follows: 1. The quantity of lactose routinely ingested by the individual that causes symptoms. The quantity of lactose ingested in some situations by the individual causes the above symptoms. The quantity of lactose that the individual would like to ingest (but does not due to fear of symptoms) causes the above symptoms. The quantity of lactose ingested in the course of obtaining 1,500 mg/day of calcium entirely via lactose-containing dairy products causes the above symptoms. We excluded studies that were published in non English languages and small case reports or descriptive case series with less than 100 subjects unless there are no reliable data from other higher quality studies. Only larger studies (at least 100 participants) of populations outside of the United States were included. The 50 gram dose of lactose, the quantity present in a quart of milk, was selected because this quantity of milk provides the maximal recommended daily intake of calcium (1,500 mg), and this dosage approaches the maximal daily volume of milk likely to be ingested by most Americans digestive. We excluded congenital lactase deficiency, developmental lactase deficiency among pre-term infants, milk allergies commonly seen in infants, and acute lactose intolerance (<30-60 days duration) due to such things as antibiotic use or illness. Primary lactase deficiency is also referred to as adulttype hypolactasia, lactase nonpersistence, or hereditary lactase deficiency. We attempted to review differences in prevalence in individuals of different age groups defined as: Preschool Children: 4-5 years, Children: 6-12 years, Adolescents: 13-18 years, Adults: 19-44 years, Middle Aged: 45-64 years, Aged: 65+ years, and Elderly Adults: 80 and over. Studies assessing only intestinal biopsies were reviewed for quality and applicability. A critical aspect of this question was to clearly define and differentiate between: (1) lactase nonpersisters, (2) lactose malabsorbers, and (3) lactose intolerance. There is no objective laboratory test (intestinal biopsies are rarely done and only assess lactase enzyme levels; physiologic tests: e. We defined dairy exclusion diets as low lactose diets that generally eliminate only milk and milk products or lactose free diets that eliminate all lactose products, including foods that are prepared with milk, both at home and in commercially packaged foods. We defined interventions when patients followed lactose free diets prescribed by health care professionals.
Requires skilled interpretation treatment of acute pain guidelines order generic sulfasalazine line, as artefactual flow voids giving the appearance of apparent vessel narrowing are quite common chronic pain treatment guidelines 2013 cheap 500 mg sulfasalazine fast delivery. Its main clinical application is in the very early identification of ischaemia/infarction (before changes become visible in other sequences) enabling consideration of emergency treatments of stroke such as thrombolysis alpha pain treatment center berwyn il sulfasalazine 500mg mastercard. Fat-saturation sequences A technique that selectively suppresses the signal from fat pain treatment for shingles buy sulfasalazine overnight delivery. Particularly useful for examination of the carotids in axial views of the neck in suspected carotid artery dissection (see b p elbow pain treatment exercises order sulfasalazine 500 mg with amex. It is particularly useful in the quantification of micro-haemorrhage that occurs in diffuse axonal injury after traumatic brain injury (allowing prognostication) and confirmation of suspected cavernomas (see b p pain treatment center colorado springs co cheap sulfasalazine line. Signals dependent on the levels of deoxyhaemoglobin in a region are used to infer local increases in blood flow, which in turn is taken as an indication of increased local neuronal activity. Together with carefully designed control tasks the approach can be used to localize sites of brain activation during the performance of specific tasks (such as a limb movement, or cognitive task) to infer localization of that function. Magnetic resonance spectroscopy Chemicals have specific magnetic resonance signatures, which can be used to quantify their levels in a user-defined "volume of interest", the minimum size of which is determined by scanner magnet strength but is typically ~1 cm3. Other imaging modalities Cranial ultrasound A non-invasive imaging particularly important in neonatal neurology. The distance of the reflecting structure from the probe can be inferred from the echo latency, and a real-time image of the structures underlying the probe constructed. Its use in brain imaging is limited to the period before closure of the anterior fontanelle. It is particularly useful for assessment of ventricular size, and for the detection of intra- and peri-ventricular haemorrhage (blood is echogenic), and its non-invasive and portable nature makes it particularly suitable for use in sick neonates in intensive care settings. It requires invasive arterial (or venous) catheterization (typically percutaneously via femoral artery) and injection of radio-opaque contrast to visualize the arterial tree. Very importantly, angiography also permits endovascular treatment of suitable arteriovenous malformations, aneurysms, or other vascular malformations (through the placement of endovascular coils or the use of glue embolization). In principle positron-emitting isotopes can be incorporated into a wide variety of molecules and used to reflect and map a wide variety of brain processes. These include mapping of blood flow (oxygen-15), glucose metabolism (fluoro-deoxyglucose), and the presence of particular neurotransmitter receptors (e. It is largely a research technique as an on-site cyclotron is required to manufacture the isotopes, but it has a role in identifying the location of seizure foci in evaluation of candidates for epilepsy surgery. Directly gamma-emitting isotopes can be injected and conventional gamma camera imaging used to map cerebral blood flow semi-quantitatively at the time of injection. Used in the evaluation of candidates for epilepsy surgery (by comparing ictal and inter-ictal patterns of blood flow) and in planning cerebral revascularization surgery. High Yield Neuroanatomy, Williams & Wilkins, New York, with permission of Wolters Kluwer. This is essentially all the white matter superior to the lateral ventricles, extending fully anteriorly and posteriorly (area A in Figure 2. The name comes from the approximately semi-circular outline (in each hemisphere) of this area in axial views. Corpus striatum the internal capsule, basal ganglia and the intervening white matter (C in Figure 2. Trigone the triangular junction of the temporal and occipital horns of the lateral ventricle and the main body (see location 42 in Figure 2. Even numbers refer to right-sided electrodes, odd numbers to left- sided electrodes. The presence of normal age-appropriate background rhythms is a strong indicator of intact cortical function suggesting cortical sparing in any process under evaluation. The individual, and family and/or carer should be made aware that such activation procedures may induce a seizure and they have a right to refuse. A technical report will follow each record along with an opinion on the relevance of the findings to the clinical situation. These findings are so common in the general population that they offer little or no support for a diagnosis of epilepsy: beware of over-interpreting them. A non-specific indicator of major suppression of cortical function seen (for example) in deep barbiturate anaesthesia, and profound encephalopathy of any cause. Bottom (C) generalized 3Hz spike wave activity typical of childhood absence epilepsy (see b p. The slow activity prior to the onset of the 3Hz activity reflects hyperventilation-related changes. A stimulating electrode is placed at two defined points along a given nerve pathway a known distance apart. Supra-maximal stimulation is used to ensure the fastest fibres are being stimulated. Nerve conduction studies Measure amplitude, latency, configuration, and conduction velocities of motor, sensory, or mixed nerves (Figure 2. Conduction velocity is dependent on the diameter and degree of myelination of the neuron. Patchy demyelination causes attenuation of the compound muscle action stimulated proximally but stimulation nearer the muscle (distal to the patchy demyelination) gives normal results. The late responses these studies may be abnormal even when distal motor responses are normal as they test proximal function-they are useful in assessing radiculopathies, plexopathies, polyneuropathies, and proximal mononeuropathies. Asymmetry of response is key to determining abnormalities: under normal circumstances, latencies should not differ between sides by >1 ms. F-wave F-wave studies are used to assess the proximal segments of the motor nerve function, and are performed in combination with the examination of motor nerves. The response is then fired down along the axon and causes a minimal contraction of the muscle. Unlike the H-reflex, the F-wave is always preceded by a motor response and its amplitude is rather small, usually in the range of 0. Electrophysiologic correlates of peripheral nervous system maturation in infancy and childhood. Each potential is produced by groups of fibres responding to a single motor neuron. Appearances can be ambiguous, however, and it is important to interpret the findings in the light of other aspects of the clinical picture, the technical adequacy of the study and the experience of the neurophysiologist. These are sharp, bi-phasic and of short duration with low amplitude potentials of about 100 V. They indicate collateral re-innervation by surviving neurons with an increased territory. There are age-dependent normal values for jitter, measurement of which is expressed as mean consecutive difference or mean sorted difference between the trigger potential and an adjacent muscle fibre potential. The large recording surface picks up electrical activity from all muscle fibres from a single motor unit. Quantitative electromyography Motor unit morphology can be quantified by analysing the duration, amplitude, phases, turns, area or area/amplitude ratio for 20 or more randomly selected simple motor units from a given muscle. They are passive responses that can be elicited in the uncooperative (ill or young) child. As visual acuity returns, amplitude will improve but delayed latency is typically permanent. Temporary elevations may occur immediately after seizures but these tend to be modest. Urine organic acids Abnormal profiles may be present all the time or only during metabolic decompensation. Many substances may create artefactual changes including concomitant valproate administration. There is a risk of false negatives if urine is too dilute or the child has recovered from metabolic decompensation. Urine amino acids Analysis may be used to diagnose a metabolic defect or to monitor treatment of aminoacidurias. Urinary mucopoly- and oligosaccharide screen Urine mucopolysaccharide screening tests uses 2-D electrophoresis to detect greatly elevated levels of glycosaminoglycans in mucopolysaccharidoses. Additionally, thin-layer chromatography is performed to identify the oligosaccharidoses (including mannosidosis and fucosidosis). Urine sulphites the presence of sulphites in urine indicates molybdenum cofactor or sulphite oxidase deficiency. There is a significant false negative risk if the sample is not tested within 20 min of voiding due to degradation of sulphites. Urine alpha-aminoadipic semialdehyde A-aminoadipic semialdehyde dehydrogenase deficiency causes pyridoxine dependent seizures. Urine creatinine, creatine, and guanidinoacetate Disorders of creatine metabolism may be suspected from a low serum creatinine concentration. Acidosis may accompany many metabolic conditions, notably mitochondrial cytopathies, organic acidopathies, and catabolic states. Either urine organic acids (in acute episodes) or acylglycines should be analysed. Ammonia Hyperammonaemia is an important indication of urea cycle disorders and/ or liver dysfunction; however, artefactually raised ammonia levels due to improper sample collection are common. Blood obtained should be free flowing, and the laboratory forewarned to accept and promptly handle the sample, which should be transported on ice as red cells and glutamine in the serum can otherwise both also release ammonia. Many laboratories screen for a panel of enzymes; however, this may not include the enzyme you are specifically interested in! It is important that the laboratory has appropriate quality assurance procedures in place. This sample can be fixed and prepared for electron microscopy for inclusion bodies, which can be useful in the diagnosis of lysosomal disease and neuronal ceroid lipofuscinosis. A small number of acanthocytes may be seen in other forms of severe haemolytic anaemia, particularly after splenectomy. Lactate Free flowing blood is typically collected immediately into perchloric acid to deproteinize it. For the laboratory to interpret the levels of the volume of added blood must be accurately known: this is usually done by pre-weighing the tube. Metaphase spreads are selected, and the chromosomes are arranged in descending order by size and compared with a standard. Techniques constantly improve in terms of the types of staining available, and the analysis is now often computerized. This often makes it worth repeating the test if it has not been done for some years. Comparative genome hybridization this technique is becoming increasingly available and may replace routine karyotyping in the near future. Balanced rearrangements, inversions or other rearrangements that do not alter total copy number will not be detected. Ring chromosome 20 mosaicism this is a recognized syndrome of severe epilepsy and learning difficulties with severe behavioural features. Ring chromosome 20 mosaicism should be specified if this is a consideration so that more cells are examined: examination of 50 cells will identify 6% mosaicism with 95% confidence. Stop and maintain the cuff for 1 min, then release the cuff, and take blood for lactate and ammonia at 2 and 12 min. Transferrin is a sensitive and convenient marker, secreted by the liver and normally present in different isoforms due to differences in glycosylation. Biotinidase the phenotypic range of this treatable deficiency state is broad (see b p. Consider testing especially where there is hypotonia, severe infantile epilepsy, alopecia, rashes, and hearing loss.
Purchase 500mg sulfasalazine with visa. Acupuncture and Herbal Treatment for Headache and Stomach Pain.